 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...9293949596979899100101102...123124» |
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P3 trial, Metastases: Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) (clinicaltrials.gov) - Dec 10, 2020
P3, N=790, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC). () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_710;
P2
OS in TACE plus sorafenib in TACTICS trial showed the longest OS (36.2 mo) with the longest ?OS (5.4 mo) as compared with the previous 5 TACE combination trials. The major reason for negative OS result was speculated that many post-trial active treatments were performed in control arm (76.3%), which implies that OS endpoint in TACE combination trial may not be feasible anymore in current era of sequential therapy with many active locoregional and systemic treatments.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Results from the gastric cancer cohort. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_520;
P2
In patients with advanced gastric cancer who received 2 prior lines of therapy, lenvatinib plus pembrolizumab demonstrated promising antitumor activity and a manageable safety profile. Based on these data, enrollment in the gastric cancer cohort has been expanded to 100 patients.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Low energy amplitude modulated radiofrequency electromagnetic fields to show antitumor effect in combination with standard treatment or as monotherapy in patients with advanced hepatocellular carcinoma. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_269;
EMF showed objective anti-tumor effect in combination with TKI or as single modality in advanced HCC patients. EMF showed improvement in overall survival in comparison with the historical control group supporting future development as a novel systemic treatment modality in advanced HCC patients.
- ascrinvacumab (GT90001) / Suzhou Kintor, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Safety and efficacy of combination of GT90001, an anti-activin receptor-like kinase-1 (ALK-1) antibody, and nivolumab in patients with metastatic hepatocellular carcinoma (HCC). () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_263;
P1/2
The combination of GT90001 with nivolumab showed a manageable safety profile, and no new safety signals were identified. The promising preliminary antitumor activities show the potential of GT90001 combined with nivolumab as second-line treatment for advanced HCC.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_258;
P2
Lenvatinib plus pembrolizumab demonstrated encouraging efficacy and manageable toxicity in patients with advanced BTC who had received 1 line of prior therapy. Based on these data, enrollment in the BTC cohort has been expanded to 100 patients.
- lenvatinib / Generic mfg.
[VIRTUAL] Early tumor marker decrease to predict the efficacy of combination therapy with lenvatinib plus anti-PD-1 antibodies in unresectable hepatocellular carcinoma (uHCC). () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_241;
A tumor marker decrease was seen in most patients as early as 2-3 weeks after the initiation of the combination therapy. Early on-treatment AFP or PIVKA-II decrease may serve as a predictor for objective response for patients with uHCC receiving combination anti-angiogenic and immune therapy.
- lenvatinib / Generic mfg.
[VIRTUAL] Post hoc analysis in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who progressed to Child-Pugh B (CPB) liver function in the phase III REFLECT study of lenvatinib (LEN). () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_235;
In this post hoc analysis of pts in REFLECT, we examine the key efficacy and safety results for LEN-treated pts who progressed to CPB by week 8. This post hoc analysis is limited by its descriptive nature; however, the results indicate that further study of LEN in CPB pts with uHCC is warranted.
- Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Comparison of systemic therapy efficacy in advanced hepatocellular carcinoma: Systematic review and frequentist network meta-analysis of randomized controlled trials. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_230;
In the first line setting, atezolizumab plus bevacizumab may be the superior regimen whereas lenvatinib may be considered as the initial option when robust tumor responses are preferred. In the second line setting, cabozantinib may be the preferred option including in cases when robust tumor responses are favored.
- lenvatinib / Generic mfg.
[VIRTUAL] When will it be better? Lenvatinib combined with TACE for unresectable hepatocellular carcinoma: A retrospective analysis of real-world evidence in China. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_218;
This is to date the first real-world data of the combination timing of lenvatinib with TACE in u-HCC patients. Early-combination strategy may be a better option for the u-HCC patients with a longer mPFS .
- lenvatinib / Generic mfg.
[VIRTUAL] The dose-optimisation of lenvatinb for patients with unresectable hepatocellular carcinoma in clinical practice: A retrospective analysis of real-world evidence in China. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_217;
The dose-escalation strategy may be an alternative approach to prolong lenvatinib treatment period, with comparable efficacy and more tolerance. More data are needed to confirm the long-term efficacy and safety of the dose-escalation strategy.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Contemporary real-world treatment patterns and outcomes of patients with advanced/metastatic hepatocellular carcinoma receiving second-line systemic therapy in the United States. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_216;
In this contemporary national real-world cohort of patients with advanced/ metastatic HCC, a third of patients who received 1L therapy subsequently received 2L therapy. Next steps include investigating factors associated with non-receipt of 2L therapy, sequencing of therapies when multiple lines of therapies are received, and evaluating outcomes by type of agent received in 2L and beyond.
- lenvatinib / Generic mfg.
[VIRTUAL] Posttreatment after lenvatinib in patients with advanced hepatocellular carcinoma. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_215;
Sorafenib was not considered a candidate posttreatment agent after lenvatinib, except in a limited number of patients who discontinued lenvatinib without radiological progression. Regorafenib is a potential posttreatment agent after lenvatinib.
- lenvatinib / Generic mfg.
[VIRTUAL] Efficacy and safety of lenvatinib in the real-world treatment of hepatocellular carcinoma: Results from a Canadian multicenter database (HCC CHORD). () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_212;
LEN use in second or later lines also showed similar outcomes, although more conclusions are difficult to draw due to the small numbers. LEN appears to be effective and safe in real world practice outside of Asia in first- and second-to-fourth line treatment of HCC.
- lenvatinib / Generic mfg.
[VIRTUAL] Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients treated in United States clinical practices. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_210;
Second-line (2L) treatment was initiated in 32 patients, with immunotherapy (50%), sorafenib (31%) and regorafenib (9%) being most common. Results from this retrospective real-world study in an U.S. population affirm the clinical effectiveness of 1L lenvatinib monotherapy among patients with uHCC.
- Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Tecentriq (atezolizumab) / Roche
[VIRTUAL] Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational, multicenter retrospective study. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_209;
Results from this retrospective real-world study in an U.S. population affirm the clinical effectiveness of 1L lenvatinib monotherapy among patients with uHCC. Second-line treatment with MKIs, mostly sorafenib and lenvatinib, showed comparable efficacy and manageable toxicities in patients with advanced HCC after disease progression on atezolizumab-bevacizumab.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Results from the gastric cancer cohort. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_187;
P2
In patients with advanced gastric cancer who received 2 prior lines of therapy, lenvatinib plus pembrolizumab demonstrated promising antitumor activity and a manageable safety profile. Based on these data, enrollment in the gastric cancer cohort has been expanded to 100 patients.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_81;
P2
In pts with previously treated advanced non–MSI-H/pMMR colorectal cancer, lenvatinib plus pembro demonstrated promising antitumor activity and a manageable safety profile. Enrollment in the colorectal cohort was expanded to 100 pts.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: LENABC: Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer (clinicaltrials.gov) - Dec 7, 2020
P2, N=50, Recruiting, Sponsor: Peking Union Medical College Hospital
- || lenvatinib / Generic mfg.
Clinical, Journal: Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: a multicenter analysis. (Pubmed Central) - Dec 5, 2020
Lenvatinib treatment offers a benefit in highly advanced HCC (tm50%LO or VP4) patients with good liver function or nodular type tumor. The various characteristics identified in this study might be useful as indicators of lenvatinib treatment in highly advanced HCC with tm50%LO or VP4, which are considered very refractory cancers.
- |||| Stivarga (regorafenib) / Bayer, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
#APPLESTC2020 Dr Andrew Zhu @MGHMedicine now talking about promising data of #Immunotherapy + TKIs. #lenvatinib @EisaiUS #Cabozantinib @ExelixisInc #regorafenib @Bayer (Twitter) - Dec 4, 2020
- || Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Clinical, Review, Journal: Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. (Pubmed Central) - Dec 3, 2020
This trend has changed over the last 2 years with several compounds, such as lenvatinib (in first-line) and regorafenib, cabozantinib, ramucirumab and nivolumab (in second-line), showing clinical benefit...Conversely, PFS with a HR between 0.6-0.7, despite significant, was not associated with better survival, and thus these magnitudes are considered uncertain surrogates. In the current review, we discuss the reasons for positive or negative phase III trials in advanced HCC, and the strengths and limitations of clinical surrogate endpoints (PFS, TTP and objective response rate [ORR]) to predict survival.
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov) - Dec 2, 2020
P1, N=1000, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
In the current review, we discuss the reasons for positive or negative phase III trials in advanced HCC, and the strengths and limitations of clinical surrogate endpoints (PFS, TTP and objective response rate [ORR]) to predict survival. Trial completion date: Dec 2023 --> May 2025 | Trial primary completion date: Jun 2021 --> May 2025
- | Welireg (belzutifan) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Metastases: LITESPARK-011: A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) (clinicaltrials.gov) - Dec 1, 2020
P3, N=708, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Dec 2023 --> May 2025 | Trial primary completion date: Jun 2021 --> May 2025 Not yet recruiting --> Recruiting
- | lenvatinib / Generic mfg.
Biomarker, Journal: Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer. (Pubmed Central) - Nov 28, 2020
Patients with RR-DTC with a high tumor burden and tumor-related symptoms had significantly worse prognosis. Greater tumor reduction after starting lenvatinib may lead to better prognosis, irrespective of pretreatment high tumor growth rate.
- || Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib. (Pubmed Central) - Nov 28, 2020
Most adverse events were grades 1-2, and the majority of patients tolerated the side effects. Our study confirms the efficacy and safety of lenvatinib as second-line and later line treatment for patients with unresectable HCC who received sorafenib in clinical practice.
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, PD(L)-1 Biomarker: TALENT: Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC (clinicaltrials.gov) - Nov 27, 2020
P2, N=27, Not yet recruiting, Sponsor: Sun Yat-sen University
Our study confirms the efficacy and safety of lenvatinib as second-line and later line treatment for patients with unresectable HCC who received sorafenib in clinical practice. N=40 --> 27
- | Nexavar (sorafenib) / Bayer, Amgen
Journal: Comparison of therapeutic outcomes of Sorafenib and Lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis. (Pubmed Central) - Nov 27, 2020
N=40 --> 27 Both SOR and LEN treatments showed a clinically comparable therapeutic efficacy as the first-line treatments for u-HCC patients in an MTA sequential therapy.
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, PD(L)-1 Biomarker: Lenvatinib and Pembrolizumab Combination Therapy in HPV-associated Recurrent Respiratory Papillomatosis Patients with Laryngeal, Tracheal, And/or Pulmonary Involvement (clinicaltrials.gov) - Nov 26, 2020
P2, N=21, Not yet recruiting, Sponsor: Massachusetts General Hospital
- || lenvatinib / Generic mfg.
Clinical, Journal: Sequential Analysis of Neutrophil-to-lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib. (Pubmed Central) - Nov 25, 2020
NLR values vary before and during lenvatinib treatment, suggesting that this ratio can reflect disease activity of RR-DTC. NLR can supportively be used as a tumor marker of RR-DTC and an indicator for starting lenvatinib treatment.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors (clinicaltrials.gov) - Nov 24, 2020
P2, N=50, Recruiting, Sponsor: Peking Union Medical College Hospital
NLR can supportively be used as a tumor marker of RR-DTC and an indicator for starting lenvatinib treatment. Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Apr 2020 --> Apr 2021
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date, PD(L)-1 Biomarker, Metastases: Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 23, 2020
P2, N=76, Recruiting, Sponsor: Peking Union Medical College Hospital
Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Apr 2020 --> Apr 2021 Initiation date: Oct 2020 --> Jul 2020
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 23, 2020
P=N/A, N=30, Not yet recruiting, Sponsor: RenJi Hospital
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Combination therapy: Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma (clinicaltrials.gov) - Nov 23, 2020
P2, N=343, Active, not recruiting, Sponsor: Eisai Inc.
Initiation date: Oct 2020 --> Jul 2020 Trial completion date: Nov 2020 --> Jul 2021
- lenvatinib / Generic mfg.
[VIRTUAL] Lenvatinib (LEN) plus anti-PD-1 antibodies vs LEN alone for advanced hepatocellular carcinoma (HCC): A real-world study () - Nov 22, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1669;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- || Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal: Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. (Pubmed Central) - Nov 21, 2020
Multiple clinical trials of combination immunotherapy have been recently completed, but interpretation of the results is hampered by small samples sizes and discordant outcomes. This review summarizes recent data on emerging treatments for neuroendocrine neoplasms.
- | Opdivo (nivolumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition, MSi-H Biomarker, PD(L)-1 Biomarker, IO Biomarker: A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer. (Pubmed Central) - Nov 21, 2020
Based on substantial activity in a phase Ib/II study, the U.S. Food and Drug Administration (FDA) granted lenvatinib and pembrolizumab combination therapy accelerated approval in 2019 for the treatment of advanced endometrial cancer that is not MSI-H or dMMR and has progressed following prior therapy. Although these developments have been highly impactful, a more robust understanding of the molecular and immunologic drivers of response and resistance will be critical to optimally design next-generation studies in endometrial cancer.
- || lenvatinib / Generic mfg.
Biomarker, Clinical, Journal: Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma. (Pubmed Central) - Nov 21, 2020
Although these developments have been highly impactful, a more robust understanding of the molecular and immunologic drivers of response and resistance will be critical to optimally design next-generation studies in endometrial cancer. Reduction in tumor stain at 2 weeks after lenvatinib treatment may be an early biomarker of efficacy at 12 weeks in patients with unresectable HCC.
- || lenvatinib / Generic mfg.
Clinical, Retrospective data, Journal: Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. (Pubmed Central) - Nov 21, 2020
Among patients with PD on first-line LEN, good liver function at introduction of LEN was an important and favorable factor related to eligibility for second-line therapy. In addition, post-progression treatment with MTAs could improve the prognosis for patients who had been treated with first-line LEN.
- Tyvyt (sintilimab) / Eli Lilly
[VIRTUAL] Multiple Disciplinary Team (MDT) Treatment Could Help Convert Unresectable HCC of Late Stage to Resectable () - Nov 21, 2020 - Abstract #IHPBA2020IHPBA_790;
After MDT discussion, the comprehensive treatment was performed to downstage the tumor, including Lenvatinib (12mg/d), checkpoint inhibitor (Sintilimab Injection, 200mg q3w) and radiotherapy(GTV, 3.0Gyⅹ10 times) . MDT treatment could help downstage the late-stage HCC, convert unresectable HCC to resectable, as well as improve the prognosis of late-stage HCC.
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Hepatic Stem Cell-like Subtypes of Hepatocellular Carcinoma Revealed from the Integrative Multi-omics Analysis Using Developmental Hierarchies of the Liver () - Nov 21, 2020 - Abstract #IHPBA2020IHPBA_768;
We identified subtype-specific serum and tissue biomarkers for stem cell-like subtypes and precise therapeutic strategies for each subtype regarding immunotherapy and molecular-targeted treatment. Our findings may offer theoretical foundation of biomarker-based clinical trials for new therapeutic approaches to resectable early-stage HCC patients.
- |||| Keytruda (pembrolizumab) / Merck (MSD)
The long awaited results of the CLEAR trial of lenvatinib + pembrolizumab are positive for PFS, OS, and ORR improvement in RCC. Another IO-VEGF combination complicating frontline space in RCC. https://t.co/ZSTQfFB6wb (Twitter) - Nov 20, 2020
- |||| everolimus / Generic mfg., lenvatinib / Generic mfg.
Clinical: Lenvatinib Plus Everolimus Induces Responses in Rare RCC Population https://t.co/qBY8goCZbA via @targetedonc (Twitter) - Nov 19, 2020
- ||| everolimus / Generic mfg., lenvatinib / Generic mfg.
Clinical: Nicely done @TargetedOnc Q&A with @DrTHut on lenvatinib + everolimus. Powerful combination. Good treatment option for patients. @kidneycan (Twitter) - Nov 19, 2020
- ||| Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
Systemic therapy for HCC-- 2nd Line Therapy: If Atezo/Bev 1st line -> sorafenib/lenvatinib Can consider cabozantinib/rego too #ascoguidelines #hbpsm (Twitter) - Nov 19, 2020
- ||| Nexavar (sorafenib) / Bayer, Amgen
Systemic therapy for HCC: 1st line therapy: - Atezo/Bev (Preferred) - TKI (Sorafenib/Lenvatinib) #ascoguidelines #hbpsm (Twitter) - Nov 19, 2020
- || Stivarga (regorafenib) / Bayer, Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma. (Pubmed Central) - Nov 19, 2020
Similar adverse events were experienced by patients during consecutive treatment with sorafenib and regorafenib, which was not observed during treatment with sorafenib and lenvatinib. The obtained safety profile of sorafenib provided meaningful insights for selecting sequential therapy for patients with patients with advanced HCC.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Metastases: CLEAR trial: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Nov 19, 2020
P3, N=959, Active, not recruiting, Sponsor: Eisai Inc.
The obtained safety profile of sorafenib provided meaningful insights for selecting sequential therapy for patients with patients with advanced HCC. Trial completion date: Apr 2022 --> Apr 2021
- ||| Keytruda (pembrolizumab) / Merck (MSD)
P3 data: Other promising comination in phase IB study: Pembrolizumab + Lenvatinib Phase III study is ongoing, and soon we might have the results (Twitter) - Nov 16, 2020
- | doxorubicin hydrochloride / Generic mfg., lenvatinib / Generic mfg.
Journal: Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer. (Pubmed Central) - Nov 14, 2020
Lenvatinib promotes the antitumor effect of doxorubicin in ATC cell and xenograft model. The lenvatinib/doxorubicin combination may be a potential candidate therapeutic approach for anaplastic thyroid cancer.